The association of comorbidity measures and mortality in geriatric rehabilitation inpatients by cancer status: RESORT

Cheuk Huen Chan¹ · Claire Maddison¹ · Esme M. Reijnierse¹ · Wen Kwang Lim¹ · Andrea B. Maier¹,²

Received: 12 August 2020 / Accepted: 22 December 2020
© The Author(s) 2021

Abstract
Background Multimorbidity is highly prevalent in older adults, both those with and without cancer, and is associated with an increased risk of mortality. The aim of this study was to investigate if multimorbidity measures in geriatric rehabilitation inpatients differ in their association with mortality, dependent on a diagnosis of cancer.

Methods REStORing health of acutely unwell adulTs (RESORT) is an ongoing longitudinal inception cohort of geriatric rehabilitation inpatients. Comorbidity was measured at admission using the Charlson Comorbidity Index (CCI), age-adjusted CCI (CCI-A), Cumulative Illness Rating Scale–Geriatrics (CIRS-G) and the CIRS-G severity index. Patients were allocated to a cancer status group (no cancer, history of cancer, or active cancer). The association of comorbidity indices with mortality was analyzed using Cox regression analyses.

Results Of the 693 patients (mean age 82.2 ± 7.5 years), 523 (75.4%) had no history of cancer, 96 (13.9%) past cancer, and 74 (10.7%) active cancer. Three months post-discharge, patients with active cancer had a higher mortality risk compared to patients with no cancer (HR = 3.57, 95% CI 2.03–6.23). CCI and CCI-A scores were significantly associated with higher mortality risk in all cancer status groups.

Conclusion In geriatric rehabilitation patients, incremental CCI and CCI-A scores were associated with higher mortality in all three cancer status groups. However, patients with active cancer had a significantly higher 3-month mortality compared to those with no or past cancer, and this is likely determined by the advanced nature of the malignancies in this group.

Keywords Geriatrics · Cancer · Comorbidity · Mortality · Aged

Introduction
Cancer is a leading cause of disease burden and mortality worldwide, and the majority of diagnoses are made in individuals aged 65 years or older [1, 2]. Multimorbidity, the concurrent presence of two or more medical conditions in an individual [3], increases in prevalence with age in both the general and oncological populations [4]. It may be measured using a number of validated assessment tools, the Charlson Comorbidity Index (CCI) and Cumulative Illness Rating Scale–Geriatric (CIRS-G) version being two of the most commonly utilized [5].

The presence and severity of multimorbidity influences aspects of medical care from diagnosis to treatment decision-making, deliverability, and tolerability. Higher multimorbidity scores predict greater mortality following discharge from internal and geriatric medicine wards, particularly over longer follow-up periods [5]. However, to our knowledge, there are currently no data describing their relationship with mortality in geriatric rehabilitation patients. In patients with cancer, higher comorbidity scores are associated with higher mortality risk [6], but this varies according to cancer type and stage [7], having less impact in those with advanced or rapidly proliferating cancers [7]. In the context of higher life expectancy and the expanding treatment options for older patients diagnosed with cancer, it is likely that an increasing
number of older cancer patients with comorbidities will be admitted to geriatric rehabilitation wards. Understanding their ability to benefit from geriatric rehabilitation, and how that differs from patients without cancer, is critical to ensure appropriate care and resource utilization.

The aim of this study was to assess the association of multimorbidity, measured by the CCI and CIRS-G, with mortality 3 months post-discharge in geriatric rehabilitation patients with no, past, and active cancer in their medical history.

Methods

Study design and setting

This analysis is based on the first wave of patients participating in the RESIOring health of acutely unwell adults (RESORT) study between 15 October 2017 and 31 August 2018, an ongoing prospective, longitudinal, observational inception cohort. Patients on the geriatric rehabilitation wards of the Royal Melbourne Hospital, Melbourne, Australia, completed a standardized comprehensive geriatric assessment (CGA) at both admission and discharge. Written informed consent was obtained by the patient or a nominated proxy. Patients were excluded if they were receiving palliative care at admission, were transferred to acute care prior to consenting to the study, or lacked both the capacity to provide informed consent and a nominated proxy.

Standardized comprehensive geriatric assessment

This multi-disciplinary assessment utilizing validated tools included evaluation of each patients biological, medical, physical, cognitive, psychological, and social functioning [8]. A patient and carer questionnaire collected demographic and personal information. Primary admission reasons were categorized by diagnosis into the following categories: musculoskeletal, neurological, infection, cardiovascular, gastrointestinal and respiratory, and other (including urology, metabolic, psychiatric, vascular, hematologic, and ophthalmological). Cognitive impairment was assessed by physicians and defined as being present if it was endorsed on either the CCI or CIRS-G; dementia or mild cognitive impairment/long term neurocognitive disorder was listed in the discharge summary as a diagnosis; or in the presence of any of a standardized Mini-Mental State Examination (sMMSE) [9] score of < 24 points, a Montreal Cognitive Assessment (MoCA) [10] score < 26 points, or a Rowland Universal Dementia Assessment Scale (RUDAS) [11] score < 23 points. Activities of daily living (ADLs) and instrumental activities of daily living (iADLs) were assessed by occupational therapists using the Katz Index [12] and Lawton Brody Scale [13].

Cancer status

Patients were assigned to one of three cancer status groups. (1) No cancer: no documented history of melanoma or a solid organ or hematological malignancy. Squamous cell carcinomas and basal cell carcinomas of the skin and all typically non-malignant tumors such as meningiomas and adenomas were included in the no cancer group due to their typically benign influence on prognosis. (2) Past cancer: those with a documented history of melanoma or a solid organ or hematological malignancy that had been treated with curative intent and with no evidence of recurrence on clinical, pathological, or radiological grounds at the time of admission to geriatric rehabilitation. Patients may be on ongoing adjuvant hormone therapy for resected early breast cancer. (3) Active cancer: those with current evidence of melanoma or a solid organ or hematological malignancy on clinical, pathological, or radiological grounds that had either not yet been treated, was being treated, including those being treated with palliative intent, or was not being treated at all.

Multimorbidity measures

Multimorbidity was documented by the treating physicians at the time of admission according to the Charlson Comorbidity Index (CCI), age-adjusted Charlson Comorbidity Index (CCI-A), the Cumulative Illness Rating Scale–Geriatrics (CIRS-G) version, and the CIRS-G severity index. The CCI includes 19 prespecified conditions that are each assigned a score of 1, 2, 3, or 6 based on their relative risk of death [14]. These scores are summed to produce a final score that may range from 0 to 32. The CCI-A was calculated from the CCI, by adding a single point for each 10 years over the age 40 years [15]. The CIRS-G is an organ-system based rating scale, with the most severe condition occurring in each of 14 organ systems assigned a severity score from 0 (no problem) to 4 (extremely severe), resulting in a final score ranging from 0 to 56 [16]. The CIRS-G severity index was calculated by dividing the total CIRS-G score by the number of organ systems endorsed in the CIRS-G and provides an estimate of the overall severity of dysfunction.

Mortality

Mortality was captured 3 months post-discharge and determined from hospital records and a phone call made to all participants (or their nominated representative). Time to death was calculated from the date of admission to the date of death or censored at the last date of follow-up.
Statistical analysis

Continuous data with a normal distribution are presented as mean ± SD and continuous data that were not normally distributed were presented as medians and IQR. Categorical data were presented as counts (frequency) and percentage (%). Patient characteristics were compared between the no, past, and active cancer groups using χ² test, Fisher’s exact test, and Kruskal–Wallis tests. The CCI, CCI-A, CIRS-G, and CIRS-G severity scores were assessed as a continuous variable.

Survival analysis of the three cancer status groups was performed by the Kaplan–Meier method. The association between cancer status and mortality, and between comorbidity index score and mortality stratified by cancer status, were assessed with Cox proportional-hazard regression models expressed as HRs and 95% CI. The level of statistical significance was set to p < 0.05. All statistical analyses were performed using the Statistical Package for the Social Sciences (IBM SPSS Advanced Statistics 25.0, Armonk, NY: IBM Corp).

Results

The mean age of 693 included patients was 82.2 ± 7.5 years and 392 (56.6%) were female. Of the 693 patients, 523 (75.4%) had no history of cancer, 96 (13.9%) past cancer, and 74 (10.7%) had active cancer. Table 1 shows the patient characteristics for each of the three cancer status groups.

| Characteristics          | Total (N = 693) | Cancer status                                      |
|--------------------------|-----------------|---------------------------------------------------|
|                          |                 | No cancer (n = 523) | Past cancer (n = 96) | Active cancer (n = 74) |
| Demographics             |                 |                     |                     |                        |
| Age, years               | 693             | 82.2 ± 7.51         | 523                 | 82.3 ± 7.80            | 96                 | 82.4 ± 7.90 | 74                 | 81.8 ± 8.66 |
| Females                  | 693             | 392 (56.6)          | 523                 | 318 (60.8)             | 96                 | 45 (46.9)   | 74                 | 29 (39.2)  |
| Australian-born          | 683             | 301 (44.1)          | 517                 | 227 (43.9)             | 95                 | 45 (47.4)   | 71                 | 29 (40.8)  |
| Multimorbidity           |                 |                     |                     |                        |                     |                     |                     |                        |
| CCI score                | 693             | 2 [1–4]             | 523                 | 2 [1–3]                | 96                 | 3 [2–4]     | 74                 | 6 [3–8]    |
| CCI-A score              | 693             | 6 [5–8]             | 523                 | 6 [5–7]                | 96                 | 7 [5–8]     | 74                 | 9 [7–12]   |
| CIRS-G score             | 693             | 11.8 ± 4.69         | 523                 | 11.3 ± 4.57            | 96                 | 12.6 ± 4.78 | 74                 | 14.1 ± 4.57 |
| CIRS-G severity index    | 693             | 1.91 ± 0.43         | 523                 | 1.88 ± 0.42            | 96                 | 1.93 ± 0.40 | 74                 | 2.16 ± 0.43 |
| Functional status        |                 |                     |                     |                        |                     |                     |                     |                        |
| ADL score                | 673             | 2 [1–3]             | 510                 | 2 [1–3]                | 90                 | 1 [1–3]     | 73                 | 1 [1–2]    |
| IADL score               | 673             | 1 [0–1]             | 510                 | 1 [0–1]                | 90                 | 1 [0–2]     | 73                 | 1 [0–2]    |
| Require walking aid      | 655             | 513 (78.3)          | 492                 | 388 (78.9)             | 93                 | 73 (78.5)   | 70                 | 52 (74.3)  |
| Cognitive impairment     | 693             | 441 (63.6)          | 523                 | 343 (65.6)             | 96                 | 60 (62.5)   | 74                 | 38 (51.4)  |
| Mortality                | 693             | 74 (10.7)           | 523                 | 42 (8.0)               | 96                 | 14 (14.6)   | 74                 | 18 (24.3)  |
| Time to death, days      | 693             | 122 [114–133]       | 523                 | 122 [114–133]          | 96                 | 122.5 [113–134] | 74 | 119.5 [103–128] |

All data were reported as mean ± SD, median [IQR], or n (%)

CCI Charlson Comorbidity Index, CCI-A Charlson Comorbidity Index age-adjusted, CIRS-G Cumulative Illness Rating Scale–Geriatric, CIRS-G severity total CIRS-G score divided by the total categories endorsed in CIRS-G, ADL activities of daily living, IADL instrumental activities of daily living, SPPB Short Performance Battery Score
cancer had a higher mortality risk compared to patients with no cancer (HR = 3.57, 95% CI 2.03–6.23 and HR = 1.78, 95% CI 0.97–3.28, respectively) (Table 2).

Table 3 shows the association between the multimorbidity measures and mortality, stratified by cancer status. CCI and CCI-A scores (per one-point increment) were significantly associated with a higher risk of mortality in the no cancer group (HR = 1.21, 95% CI 1.06–1.37; HR = 1.22, 95% CI 1.08–1.37), past cancer group (HR = 1.27, 95% CI 1.06–1.52; HR = 1.26, 95% CI 1.05–1.50), and active cancer group (HR = 1.16, 95% CI 1.00–1.34; HR = 1.15, 95% CI 1.00–1.33).

CIRS-G score was associated with mortality in the no cancer group (HR = 1.09, 95% CI 1.02–1.16) but not associated in the past cancer (HR = 1.11, 95% CI 0.99–1.23) and active cancer groups (HR = 1.09, 95% CI 0.98–1.20). The CIRS-G severity index was not statistically significantly associated with mortality in any cancer status group (no cancer—HR = 1.77, 95% CI 0.87–3.61; past cancer—HR = 0.96, 95% CI 0.26–3.60; active cancer—HR = 1.44, 95% CI 0.52–4.04).

Discussion

Incremental CCI and CCI-A scores were significantly associated with higher mortality, regardless of cancer status. CIRS-G scores were significantly associated with higher mortality in patients without cancer and displayed a trend toward increased mortality risk in patients with past cancer. The CIRS-G severity scores were not associated with higher mortality risk in any of the three cancer status groups. Geriatric rehabilitation patients with active cancer had significantly higher 3-month mortality compared to those with past or no cancer.

The CCI and CIRS are two of the most commonly utilized comorbidity indices [5] and have been related to mortality in community dwelling individuals, acute inpatients, and in patients with various cancers [17]. Admission to geriatric rehabilitation typically occurs following an episode of acute illness or trauma that is associated with a deterioration in an older patient’s functional and/or cognitive abilities that prevents their return home once medical stability has been achieved.

Table 2

| Cancer status group | No cancer as reference | Past cancer as reference |
|---------------------|------------------------|--------------------------|
|                     | Unadjusted             | Adjusted                 | Unadjusted             | Adjusted                 |
|                     | HR (95% CI)            | p                        | HR (95% CI)            | p                        |
| No cancer           | 1.00                   | –                        | –                      | –                        |
| Past cancer         | 1.79 (0.98–3.28)       | 0.060                    | 1.78 (0.97–3.28)       | 0.065                    |
| Active cancer       | **3.60 (2.07–6.26)**   | **< 0.001**              | **3.57 (2.03–6.27)**   | **< 0.001**              |
|                     |                        |                          | **2.07 (1.01–4.23)**   | **0.047**                |
|                     |                        |                          | **2.13 (1.04–4.37)**   | **0.040**                |

All adjusted Cox regression analysis was adjusted for age and sex unless stated otherwise.
Despite recognition that CGA contributes to the management of such patients, and that the assessment of comorbidities is an essential component of CGA [18], it has been previously identified that there is little published research in this area [19], and to the best of our knowledge, none examining the association between commonly utilized comorbidity scores and mortality according to cancer status.

By the age of 85 years, one in two older Australians will have survived or be living with cancer [20]. The prevalence of a cancer diagnosis in our cohort, almost 25%, was less than this, reflecting the selected nature of patients admitted to geriatric rehabilitation wards. The significantly higher mortality in those with active cancer, compared to those with past and no cancer history, was expected given the majority had incurable disease.

The median CCI scores in each of the three groups were higher than that reported in other studies in geriatric rehabilitation patients [21, 22]. The higher mortality with incremental CCI and CCI-A scores in all three cancer status groups demonstrates that the association of multimorbidity with mortality is independent of cancer status in geriatric rehabilitation patients, and that this simple tool contributes information about short-term mortality in this population. The prevalence of the individual diseases comprising the CCI did not differ between the three cancer status groups, with the exception of the malignancies and a lower number of dementia patients in the active cancer group. While lower rates of dementia have been documented in some cohorts of older cancer patients [23], the difference here is likely due to selection bias, with patients with both advanced cancer and dementia following a palliative rather than rehabilitative pathway. Taken together, these findings reflect that the cancer diagnosis, which in this cohort was largely metastatic or locally advanced in nature, determined the higher mortality in the active cancer group. For these patients, careful consideration of the role and goals of geriatric rehabilitation is essential. Many patients and families prefer to spend the last part of their life in the community, rather than a hospital, and a patient-centered approach that accounts for this is critical.

The mean CIRS-G score of our cohort was also higher than that reported in other studies of geriatric rehabilitation [24] and older cancer patients [6, 25]. The past and active cancer groups had a higher prevalence of genitourinary disorders, likely explained by the number of prostate and bladder cancers in these groups. The active cancer group had a higher prevalence of hepatic/pancreatic and hematological conditions. The latter is likely explained by the association of anemia with many advanced malignancies and the difficulties in rating hematological comorbidity in patients with cancer using the CIRS, which have been previously, explored [25]. Our finding that the CCI was more consistently associated with mortality is consistent with findings in other settings, such as patients with chronic disability [26], and with studies of older cancer

| Table 3 The association of multimorbidity scores and all-cause mortality, stratified by cancer status |
|---------------------------------------------------------------|
| Multimorbidity scores | No cancer (n = 523) | Past cancer (n = 96) | Active cancer (n = 74) |
|---------------------------------------------------------------|
| CCI | 1.21 (1.07–1.36) | 1.21 (1.06–1.36) | 1.21 (1.06–1.36) |
| CCI-A | 1.23 (1.09–1.50) | 1.23 (1.08–1.50) | 1.23 (1.08–1.50) |
| CIRS-G | 1.09 (1.02–1.16) | 1.09 (1.02–1.16) | 1.09 (1.02–1.16) |
| CIRS-G severity | 1.62 (0.81–3.24) | 0.81–3.24) | 0.81–3.24) |

All adjusted Cox regression analysis was adjusted for age and sex unless stated otherwise. For the CCR, Charlon Comorbidity Index, CCA Charlon Comorbidity Index age-adjusted, CIRS-G Cumulative Illness Rating Scale–Geriatric, CIRS-G severity total CIRS-G score divided by the total categories endorsed in CIRS-G. Cox regression analysis only adjusted for sex.
patients demonstrating that the correlation between CCI and CIRS-G scores in older cancer patients is fair [27]. It has been previously documented that the two scales provide different “quantitative and qualitative” information regarding comorbidity [6, 27]. The lack of association between CIRS-G scores and mortality in the active cancer group is likely explained by the more comprehensive nature of the CIRS-G, which results in a number of minor conditions that are highly unlikely to influence the prognosis of a patient with metastatic or advanced cancer, contributing to the score, thus reducing its association with mortality in this group.

**Strengths and limitations**

The major limitation of this study is the small number of patients of each cancer type within the past and active cancer groups. As a result, analysis of differences between cancer types was not possible, nor was it possible to explore the role of previous anti-cancer treatment(s), particularly in the past cancer group.

To the best of our knowledge, this is the largest prospective study to provide detailed information regarding the comorbidity profile of geriatric rehabilitation inpatients, and the first to examine the association between multimorbidity and mortality among different cancer status groups in this setting.

**Conclusion**

While multimorbidity is associated with higher mortality in geriatric rehabilitation patients in all cancer status groups, those with active cancer have significantly higher 3-month mortality than those with no or past cancer. This is likely determined by the cancer diagnosis, often advanced, itself.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00520-020-05967-z.

**Acknowledgments** The authors acknowledge and thank all members of the multidisciplinary team at the Royal Melbourne Hospital, Royal Park Campus, for their clinical assessments of the RESORT cohort, and the @AgeMelbourne team for their role in data collection and entry.

**Author contributions** C.M., E.M.R., W.K.L., and A.B.M. had a substantial contribution to the design of the cohort and acquisition of data. C.H.C., C.M., and A.B.M. analyzed and interpreted the data. C.H.C. and C.M. drafted the manuscript and E.M.R., W.K.L., and A.B.M. critically revised it. All authors approved the final version for publication and are accountable for all aspects of their work.

**Funding** This research was funded by an unrestricted grant from the University of Melbourne received by A.B.M. and a grant from the Medical Research Future Fund (MRFF) provided by the Melbourne Academic Centre for Health (MACH).

**Data availability** Data for this analysis include patients participating in the RESORT study between 15 October 2017 and 31 August 2018. Requests for access to this data can be made in writing to the corresponding author.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no competing interests.

**Ethics approval** Ethics and governance approval was granted by the Human Research Ethics Committee of Melbourne Health (HREC/17/MH103).

**Consent to participate** All participants (or their nominated proxy) provided written informed consent. This research was performed in accordance with the 1964 Declaration of Helsinki and its later amendments.

**Consent for publication** All authors consent to publication of the submitted work.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. World Health Organization. Latest global cancer data: cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. GLOBOCAN2018
2. American Cancer Society. Global Cancer Facts & Figures 4th Edition. Atlanta: American Cancer Society2018
3. Salive ME (2013) Multimorbidity in older adults. Epidemiol Rev 35:75–83. https://doi.org/10.1093/epirev/mxs009
4. Sogaard M, Thomsen RW, Bossen KS, Sorensen HT, Norgaard M (2013) The impact of comorbidity on cancer survival: a review. Clin Epidemiol 5(Suppl 1):3–29. https://doi.org/10.2147/CLEP.S47150
5. Soh CH, Ul Hassan SW, Sacre J, Maier AB (2020) Morbidity measures predicting mortality in inpatients: a systematic review. J Am Med Dir Assoc 21(4):462–468. https://doi.org/10.1016/j.jamda.2019.12.001
6. Extermann M (2000) Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 35(3):181–200. https://doi.org/10.1016/s1040-8428(00)00090-1
7. Read WL, Tierney RM, Page NC, Costas I, Govindan R, Spitznagel EL et al (2004) Differential prognostic impact of comorbidity. J Clin Oncol 22(15):3099–3103. https://doi.org/10.1200/jco.2004.08.040
8. Ellis G, Gardner M, Tsiachristas A, Langhorne P, Burke O, Harwood RH, Conroy SP, Kircher T, Somme D, Saltvedt I, Wald H, O’Neill D, Robinson D, Shepperd S, Cochrane Effective Practice.
and Organisation of Care Group (2017) Comprehensive geriatric assessment for older adults admitted to hospital. Cochrane Database Syst Rev 9:CD006211. https://doi.org/10.1002/14651858.CD006211.pub3
9. Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198. https://doi.org/10.1016/0022-3956(75)90026-6
10. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53(4):695–699. https://doi.org/10.1111/j.1532-5415.2005.53221.x
11. Storey JE, Rowland JTJ, Basic D, Conforti DA, Dickson HG (2004) The Rowland Universal Dementia Assessment Scale (RUDAS): a multicultural cognitive assessment scale. Int Psychogeriatr 16(1):13–31. https://doi.org/10.1017/s1041610204000043
12. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW (1963) Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA. 185:914–919. https://doi.org/10.1001/jama.1963.03060102004016
13. Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 9(3):179–186
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383. https://doi.org/10.1016/0021-9681(87)90171-8
15. Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(11):1245–1251. https://doi.org/10.1016/0895-4356(94)90129-5
16. Miller MD, Towers A (1991) A manual of guidelines for scoring the Cumulative Illness Rating Scale for Geriatrics (CIRS-G)
17. Degroot V, Beckerman H, Lankhorst G, Bouter L (2003) How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 56(3):221–229. https://doi.org/10.1016/s0895-4356(02)00585-1
18. Parker SG, McCue P, Phelps K, McCleod A, Arora S, Nockels K, Kennedy S, Roberts H, Conroy S (2018) What is comprehensive geriatric assessment (CGA)? An umbrella review. Age Ageing 47(1):149–155. https://doi.org/10.1093/ageing/afx166
19. Achterberg WP, Cameron ID, Bauer JM, Schols JM (2019) Geriatric rehabilitation—state of the art and future priorities. J Am Med Dir Assoc 20(4):396–398. https://doi.org/10.1016/j.jamda.2019.02.014
20. Australian Institute of Health and Welfare. Cancer in Australia: In brief 2019. Canberra: AIHW2019. Cat. no. CAN 126
21. Kabboord AD, Godfrey D, Gordon AL, Gladman JRF, Van Eijk M, van Balen R et al (2020) The modified functional comorbidity index performed better than the Charlson index and original functional comorbidity index in predicting functional outcome in geriatric rehabilitation: a prospective observational study. BMC Geriatr 20(1):114. https://doi.org/10.1186/s12877-020-1498-z
22. Kabboord AD, Van Eijk M, Buijck BI, Koopmans R, van Balen R, Achterberg WP (2018) Comorbidity and intercurrent diseases in geriatric stroke rehabilitation: a multicentre observational study in skilled nursing facilities. Eur Geriatr Med 9(3):347–353. https://doi.org/10.1007/s41999-018-0043-5
23. Zeber JE, Copeland LA, Hosek BJ, Karnad AB, Lawrence VA, Sanchez-Reilly SE (2008) Cancer rates, medical comorbidities, and treatment modalities in the oldest patients. Crit Rev Oncol Hematol 67(3):237–242. https://doi.org/10.1016/j.critrevonc.2008.02.002
24. Guido D, Perna S, Peroni G, Guerriero F, Rondanelli M (2015) A comorbidity prognostic effect on post-hospitalization outcome in a geriatric rehabilitation setting: the pivotal role of functionality, assessed by mediation model, and association with the Brass index. Aging Clin Exp Res 27(6):849–856. https://doi.org/10.1007/s40520-015-0360-1
25. Wedding U, Roehrig B, Klippstein A, Steiner P, Schaeffer T, Pientka L, Höffken K (2007) Comorbidity in patients with cancer: prevalence and severity measured by cumulative illness rating scale. Crit Rev Oncol Hematol 61(3):269–276. https://doi.org/10.1016/j.critrevonc.2006.11.001
26. Rochon PA, Katz JN, Morrow LA, McGlinchey-Berroth R, Ahlquist MM, Sarkarati M et al (1996) Comorbid illness is associated with survival and length of hospital stay in patients with chronic disability. A prospective comparison of three comorbidity indices. Med Care 34(11):1093–1101. https://doi.org/10.1097/00005650-199611000-00004
27. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L (1998) Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16(4):1582–1587. https://doi.org/10.1200/jco.1998.16.4.1582

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
